بدائل البحث:
patients decrease » point decrease (توسيع البحث), treatments decreased (توسيع البحث)
larger decrease » marked decrease (توسيع البحث)
large decrease » marked decrease (توسيع البحث), large increases (توسيع البحث), large degree (توسيع البحث)
a larger » a large (توسيع البحث), _ larger (توسيع البحث), _ large (توسيع البحث)
b large » _ large (توسيع البحث), a large (توسيع البحث), _ larger (توسيع البحث)
patients decrease » point decrease (توسيع البحث), treatments decreased (توسيع البحث)
larger decrease » marked decrease (توسيع البحث)
large decrease » marked decrease (توسيع البحث), large increases (توسيع البحث), large degree (توسيع البحث)
a larger » a large (توسيع البحث), _ larger (توسيع البحث), _ large (توسيع البحث)
b large » _ large (توسيع البحث), a large (توسيع البحث), _ larger (توسيع البحث)
-
1
<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>"
منشور في 2025"…The locomotion values (traces and metrics) are in arbitrary units with larger integers representing a greater displacement of the spherical treadmill, the hemodynamic (Hbt) values (traces and metrics) are a percentage change from the normalised baseline (prior to stimulus presentation), and the corresponding time series vector is presented in seconds. …"
-
2
The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness.
منشور في 2025"…When they stop being introduced in further assembly events (i.e. introduced species do not carry any mutualistic interactions), their proportion slowly decreases with successive invasions. (B) Even though higher proportions of mutualism promote higher richness, introducing this type of interaction into already assembled large communities promotes a sudden drop in richness, while stopping mutualism promotes a slight boost in richness increase. …"
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
منشور في 2025الموضوعات: -
11
-
12
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
منشور في 2025الموضوعات: -
13
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
منشور في 2025الموضوعات: -
14
-
15
-
16
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
منشور في 2025الموضوعات: -
17
-
18
-
19
-
20